Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.
2.

Lung and bone metastases from renal cell carcinoma responsive to bisphosphonates: a case report.

Kijima T, Fujii Y, Suyama T, Okubo Y, Yonese J, Fukui I.

Int J Urol. 2008 Jun;15(6):546-7. doi: 10.1111/j.1442-2042.2008.02044.x.

3.

Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases.

Tunn UW, Stenzl A, Schultze-Seemann W, Strauss A, Kindler M, Miller K, Wirth MP, Zantl N, Schulze M, May C, Ruebel A, Birkholz K, Gruenwald V.

Can J Urol. 2012 Jun;19(3):6261-7.

PMID:
22704310
4.

Case 2. Osteonecrosis of the jaws associated with bisphosphonate therapy.

Mignogna MD, Fedele S, Lo Russo L, Ciccarelli R, Lo Muzio L.

J Clin Oncol. 2006 Mar 20;24(9):1475-7. No abstract available. Erratum in: J Clin Oncol. 2006 Jun 10;24(17):2687.

PMID:
16549843
5.
6.

Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate.

Kijima T, Fujii Y, Suyama T, Okubo Y, Yamamoto S, Masuda H, Yonese J, Fukui I.

BJU Int. 2009 Mar;103(5):620-4. doi: 10.1111/j.1464-410X.2008.08124.x. Epub 2008 Oct 16.

7.

Assessment of the impact of targeted therapy on metastatic bone disease in renal cancer.

Brown JE, Wood SL.

Eur Urol. 2014 Sep;66(3):510-1. doi: 10.1016/j.eururo.2014.03.042. Epub 2014 Apr 13. No abstract available.

PMID:
24746971
8.

A case of bone, lung, pleural and liver metastases from renal cell carcinoma which responded remarkably well to zoledronic acid monotherapy.

Miwa S, Mizokami A, Konaka H, Izumi K, Nohara T, Namiki M.

Jpn J Clin Oncol. 2009 Nov;39(11):745-50. doi: 10.1093/jjco/hyp122. Epub 2009 Oct 6.

PMID:
19808839
9.

Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer.

Saad F, Eastham JA.

Semin Oncol. 2010 Jun;37 Suppl 1:S38-44. doi: 10.1053/j.seminoncol.2010.06.001. Review.

PMID:
20682371
10.

[Zoledronic acid for bone metastases due to advanced renal cell carcinoma under chronic hemodialysis--a report of two cases].

Arima S, Shiroki R, Mori S, Maruyama T, Sasaki H, Kusaka M, Miyakawa S, Hayakawa K, Hoshinaga K.

Nihon Hinyokika Gakkai Zasshi. 2008 Jul;99(5):660-5. Japanese.

11.

Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.

Vincenzi B, Santini D, La Cesa A, Tonini G.

Cancer. 2004 May 1;100(9):1987-8; author reply 1988. No abstract available.

13.

Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma.

Tannir N, Jonasch E, Pagliaro LC, Mathew P, Siefker-Radtke A, Rhines L, Lin P, Tibbs R, Do KA, Lin SH, Tu SM.

Cancer. 2006 Aug 1;107(3):497-505.

14.

Concurrent application of bisphosphonates and external beam radiotherapy in patients with metastatic bone disease from renal cancer.

Vassiliou V, Leotsinides M, Kalogeropoulou C, Kardamakis D.

BJU Int. 2009 Aug;104(3):417-8; author reply 418. doi: 10.1111/j.1464-410X.2009.08767_3.x. No abstract available.

15.

The use of zoledronic acid in pediatric cancer patients.

August KJ, Dalton A, Katzenstein HM, George B, Olson TA, Wasilewski-Masker K, Rapkin LB.

Pediatr Blood Cancer. 2011 Apr;56(4):610-4. doi: 10.1002/pbc.22681. Epub 2010 Dec 23.

PMID:
21298747
16.

Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.

Lipton A, Colombo-Berra A, Bukowski RM, Rosen L, Zheng M, Urbanowitz G.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6397S-403S. Review.

17.

Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours.

Carter JA, Joshi AD, Kaura S, Botteman MF.

Pharmacoeconomics. 2012 May;30(5):373-86. doi: 10.2165/11631390-000000000-00000. Review.

PMID:
22500986
18.

Zoledronic acid enhances the effect of radiotherapy for bone metastases from renal cell carcinomas: more than a 24-month median follow-up.

Takeda N, Isu K, Hiraga H, Shinohara N, Minami A, Kamata H.

J Orthop Sci. 2012 Nov;17(6):770-4. doi: 10.1007/s00776-012-0294-9. Epub 2012 Oct 2.

PMID:
23053582
19.

Orbital inflammatory disease after intravenous infusion of zoledronate for treatment of metastatic renal cell carcinoma.

Phillips PM, Newman SA.

Arch Ophthalmol. 2008 Jan;126(1):137-9. doi: 10.1001/archophthalmol.2007.17. No abstract available.

PMID:
18195236
20.

Complete clinical and biological response to zoledronic acid in castrate-resistant prostate cancer metastatic to bone.

Pouessel D, Culine S.

Anticancer Drugs. 2012 Jan;23(1):141-2. doi: 10.1097/CAD.0b013e32834bede5.

PMID:
21934600

Supplemental Content

Support Center